Global Factors Influencing the Rapid Evolution of the GMP Cell Therapy Consumables Market

The GMP cell therapy consumables market is poised for remarkable expansion in the coming years, driven by significant advancements and increasing demand within the biopharmaceutical sector. As cell therapies become more commercialized and production processes scale up, the market is set to witness robust growth fueled by technological innovations and heightened regulatory standards. Let's explore the market's size projections, key players, growth drivers, and segmentation in detail.

Anticipated Market Growth and Size of the GMP Cell Therapy Consumables Market
The GMP cell therapy consumables market is forecasted to experience rapid growth, reaching a valuation of $73.96 billion by 2030. This represents an impressive compound annual growth rate (CAGR) of 26.6%. The surge in market size is primarily due to the expanding commercialization of cell therapies, heightened demand for scalable GMP-compliant manufacturing processes, broadening gene and immunotherapy development pipelines, increased focus on automating production, and stricter regulatory oversight in cell therapy manufacturing. Throughout the forecast period, notable market trends include a rising preference for GMP-compliant consumables, widespread adoption of single-use bioprocessing technologies, growth in automated cell processing systems, and the development of standardized cell culture solutions with a strong emphasis on quality and regulatory adherence.

Download a free sample of the gmp cell therapy consumables market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12014&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Mar_PR

Leading Companies Driving Innovation in the GMP Cell Therapy Consumables Market
Several prominent companies hold key positions in the GMP cell therapy consumables market. Notable market leaders include Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Sartorius AG, Corning Incorporated, Avantor Inc., Fresenius Kabi AG, Miltenyi Biotec, Bio-Techne Corp, STEMCELL Technologies Inc., FUJIFILM Irvine Scientific Inc., BioLife Solutions Inc., PromoCell GmbH, PeproTech Inc., Sino Biological Inc., Wilson Wolf Corporation, Cellexus Ltd., MaxCyte Inc., BioLegend Inc., Repligen Corporation, and Terumo Corporation.

A significant recent development occurred in March 2023, when Sartorius AG, a German provider of bioprocess solutions and single-use technologies for biopharma, acquired Polyplus for around €2.4 billion (approximately US$2.6 billion). This strategic acquisition strengthens Sartorius' leadership in supplying essential upstream technologies for cell and gene therapies. By integrating Polyplus's transfection reagents and GMP-grade plasmid DNA with its existing portfolio of cell culture media and bioprocess materials, Sartorius enhances its capabilities to support viral vector manufacturing workflows essential for advanced therapies. Polyplus, based in France, specializes in innovative upstream technologies for cell and gene therapies, producing high-quality transfection reagents and GMP-grade plasmid DNA crucial for viral vector production in advanced medicinal treatments.

View the full gmp cell therapy consumables market report:
https://www.thebusinessresearchcompany.com/report/gmp-cell-therapy-consumables-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Mar_PR

Key Drivers Supporting Growth in GMP Cell Therapy Consumables
A pivotal driver of growth in this market is the development and availability of GMP-compliant CD34+ hematopoietic stem cells (HSCs) for use in advanced therapies. These stem cells, characterized by the CD34 marker and produced under strict GMP conditions, are vital for various therapeutic applications. Industry players are actively advancing these products to meet the evolving needs of cell therapy manufacturing.

For example, in April 2024, OrganaBio, a US-based pharmaceutical company, introduced HematoPAC-HSC-CB-GMP, an on-demand source of GMP-compliant CD34+ HSCs derived from fresh human cord blood. Leveraging expertise in cell isolation and GMP manufacturing processes, OrganaBio can produce large quantities of highly viable CD34+ HSCs within 24 hours of collection. This product launch aims to accelerate the development of next-generation treatments for blood cancers and genetic disorders, highlighting the market's focus on providing high-quality, ready-to-use stem cell therapies.

How the GMP Cell Therapy Consumables Market is Structured
The GMP cell therapy consumables market is organized into several key segments to provide a thorough view of the industry:

1) By Product: This includes Kits, Reagents or Molecular Biology Reagents, Growth Factors or Cytokines and Interleukins, and Other Products.
2) By Cell Therapy Type: This covers NK Cell Therapy, Stem Cell Therapy, and T-Cell Therapy.
3) By Process Stage: This segment includes Cell Collection and Characterization or Sorting and Separation, Cell Culture and Expansion or Preparation, Cryopreservation, Cell Processing and Formulation, and Cell Isolation and Activation.
4) By End-Use: Divided into Clinical and Commercial applications.

Further sub-segments include:
- Kits such as Cell Culture Kits, Cell Isolation Kits, and Transfection Kits.
- Reagents or Molecular Biology Reagents comprising Buffers and Solutions, Enzymes, and Staining Reagents.
- Growth Factors or Cytokines and Interleukins, including Hematopoietic Growth Factors and Immunomodulatory Cytokines.
- Other Products like Cell Culture Vessels, Media, and Supplements.

This detailed segmentation helps stakeholders identify specific areas of opportunity and tailor their strategies to meet the evolving demands of the GMP cell therapy consumables market.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.